Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 8/10/20 → 1/30/27 |
Funding
- Merck Sharp & Dohme Corporation: $198,704.00
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants
- Hao, Zhonglin (PI)
- Zinner, Ralph (Former PI)